Please ensure Javascript is enabled for purposes of website accessibility

Inovio's Latest COVID Vaccine Results: Too Little, Too Late?

By Keith Speights and Brian Orelli, PhD - Updated Jun 28, 2021 at 8:39AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Maybe not -- especially outside of the U.S.

Inovio Pharmaceuticals (INO -3.05%) recently reported encouraging results from a phase 2 study of its COVID-19 vaccine candidate INO-4800. However, the company lags well behind the current leaders in the COVID-19 vaccine market. In this Motley Fool Live video recorded on May 12, Motley Fool contributors Keith Speights and Brian Orelli discuss Inovio's latest clinical results.

Keith Speights: Inovio Pharmaceuticals reported its phase 2 results for its COVID-19 vaccine candidate, INO-4800, earlier this week, Brian, what were the highlights from Inovio's results? Do you think this might be a case of the biotech simply being too little and too late to make a difference in the COVID vaccine race?

Brian Orelli: The phase 2 trial was measuring antibodies, they are not measuring the efficacy of whether it protects people against COVID-19. That wasn't the purpose of the phase 2 part of the trial. It did produce more antibodies, a higher level of antibodies, in the higher dose than in the lower dose, so that's exactly what you would expect. The same thing for T-cells. Produced more T-cells in the higher dose than the lower dose.

On the safety side, the company noted that the side effects weren't worse for the second dose than the first dose. That's actually interesting and could potentially maybe give it an advantage over Pfizer and Moderna that seem to have pretty strong side effects on the second dose that was mild, but a lot of people have them. We're planning on taking the higher dose into the phase 3. Unfortunately, the company didn't give any updates for how it plans to carry out the phase 3. I'll stop short of saying too little or too late, but maybe it was too little data, certainly not enough to gain approval.

Whether they're too late depends on whether Inovio can figure out how to run a phase 3. They need to find a region that doesn't have access to vaccines and a high rate of COVID-19 to run the phase 3 clinical trial. Then if they do that, the question is, will the FDA accept the vaccine for authorization or maybe even for approval if they're running a clinical trial outside the United States. Those are questions that investors in Inovio need to figure out in trying to value the company. It's how can they run a phase 3, and then if they can run a phase 3, can they get authorization or approval in the United States?

Speights: You and I have talked before about Inovio and some of the other vaccine makers that aren't in the lead positions, that they may have an easier time getting authorizations and marketing their vaccines outside of the U.S.

Orelli: I don't know if that's going to be the inevitable thing for Inovio. I mean, it's interesting because I don't think that if you develop a new flu vaccine, I'm not sure that you have to show efficacy or whether you just have to show antibodies. Maybe at some point when we get into the point where we're no longer in a pandemic, maybe companies can develop coronavirus vaccines based solely on the ability to create antibodies.

Speights: I think you could very well be right. There might be at least another year or so before we get to that point, but it wouldn't surprise me that something happens exactly along the lines of what you're saying.

Brian Orelli, PhD has no position in any of the stocks mentioned. Keith Speights owns shares of Pfizer. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$2.71 (-3.05%) $0.09
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$49.81 (0.13%) $0.07
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$167.91 (-5.02%) $-8.88

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
403%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.